A financial perspective on the topical treatment of onychomycosis.
Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC. Electronic address: lagrew@musc.edu.
James Prewitt
JP
Lagrew
D000287:Administration, Topical; D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use*; D001896:Boron Compounds / Q000191:economics / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D014009:Onychomycosis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D016896:Treatment Outcome; D014230:Triazoles / Q000191:economics / Q000627:therapeutic use*
D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D014230:Triazoles; C431707:efinaconazole; C512998:tavaborole